345 related articles for article (PubMed ID: 12018633)
21. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
[TBL] [Abstract][Full Text] [Related]
22. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A
J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
[TBL] [Abstract][Full Text] [Related]
24. Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study.
Tagawa M; Hamano T; Nishi H; Tsuchida K; Hanafusa N; Fukatsu A; Iseki K; Tsubakihara Y
PLoS One; 2014; 9(12):e114678. PubMed ID: 25494334
[TBL] [Abstract][Full Text] [Related]
25. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?
Ghazali A; Fardellone P; Pruna A; Atik A; Achard JM; Oprisiu R; Brazier M; Remond A; Morinière P; Garabedian M; Eastwood J; Fournier A
Kidney Int; 1999 Jun; 55(6):2169-77. PubMed ID: 10354266
[TBL] [Abstract][Full Text] [Related]
26. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
27. Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L.
Yamada S; Ueki K; Tokumoto M; Suehiro T; Kimura H; Taniguchi M; Fujimi S; Kitazono T; Tsuruya K
Ther Apher Dial; 2016 Feb; 20(1):31-9. PubMed ID: 26482334
[TBL] [Abstract][Full Text] [Related]
28. Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study.
Asada S; Yokoyama K; Miyakoshi C; Fukuma S; Endo Y; Wada M; Nomura T; Onishi Y; Fukagawa M; Fukuhara S; Akizawa T
Clin Exp Nephrol; 2020 Jul; 24(7):630-637. PubMed ID: 32236781
[TBL] [Abstract][Full Text] [Related]
29. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
[TBL] [Abstract][Full Text] [Related]
30. Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis.
Block GA; Yusuf AA; Danese MD; Wirtz HS; Hu Y; Do TP; Cooper K; Gilbertson DT; Bradbury BD; Collins AJ
BMC Nephrol; 2016 Nov; 17(1):166. PubMed ID: 27814753
[TBL] [Abstract][Full Text] [Related]
31. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
32. Treatment of hyperphosphatemia: the dangers of high PTH levels.
Bacchetta J
Pediatr Nephrol; 2020 Mar; 35(3):493-500. PubMed ID: 31696357
[TBL] [Abstract][Full Text] [Related]
33. Relation between serum calcium, phosphate, parathyroid hormone and 'nondipper' circadian blood pressure variability profile in patients with normal renal function.
Kanbay M; Isik B; Akcay A; Ozkara A; Karakurt F; Turgut F; Alkan R; Uz E; Bavbek N; Yigitoglu R; Covic A
Am J Nephrol; 2007; 27(5):516-21. PubMed ID: 17703091
[TBL] [Abstract][Full Text] [Related]
34. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
Ogata H; Koiwa F; Shishido K; Kinugasa E
Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
[TBL] [Abstract][Full Text] [Related]
36. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
[TBL] [Abstract][Full Text] [Related]
37. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
[TBL] [Abstract][Full Text] [Related]
38. Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines.
Liu Y; Lee WC; Cheng BC; Li LC; Lee CH; Chang WX; Chen JB
Biomed Res Int; 2016; 2016():1523124. PubMed ID: 28003998
[No Abstract] [Full Text] [Related]
39. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?
Deger SM; Mutluay R; Derici U; Mandiralioglu F; Arinsoy T; Sindel S
Med Princ Pract; 2011; 20(1):85-9. PubMed ID: 21160221
[TBL] [Abstract][Full Text] [Related]
40. Secondary hyperparathyroidism and calcium phosphate control in a hemodialysis population.
Lim S; Gun NT
Acta Med Indones; 2007; 39(2):71-4. PubMed ID: 17485789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
